Jean-Yves Blay

发表

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.

J. Blay, M. van Glabbeke, M. Glabbeke, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved survival using specialized multidisciplinary board in sarcoma patients

F. Bertucci, S. Bonvalot, A. Cesne, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

C. Antonescu, J. Desai, J. Fletcher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.

J. Blay, W. Brugger, P. Viens, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study

Robin L. Jones, A. Cesne, S. George, 2020, British Journal of Cancer.

IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.

J. Blay, G. Montmain, C. Ménétrier-Caux, 2001, Cancer research.

Classification of current anticancer immunotherapies

S. H. van der Burg, K. Pienta, G. Giaccone, 2014, OncoTarget.

Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.

J. Blay, M. Favrot, I. Joab, 1996, Cancer research.

A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages

A. Novikov, M. Karanian, K. Chettab, 2023, Cancers.

The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma

P. Finetti, L. Shintu, F. Galland, 2023, Life Science Alliance.

The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis.

L. Mariani, O. Mir, A. D. Dei Tos, 2020, The oncologist.

The Activity of Chemotherapy in In ﬂ ammatory Myo ﬁ broblastic Tumors: A Multicenter, European Retrospective Case Series Analysis

A. Cesne, A. Gronchi, C. Morosi, 2020 .

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.

J. Blay, S. Chouaib, V. Combaret, 1990, Cancer research.

Prognostic factors in chordoma: role of postoperative radiotherapy.

J. Blay, P. Biron, J. Gérard, 1995, European journal of cancer.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

J. Blay, E. Rasmussen, J. Soria, 2019, Investigational New Drugs.

A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.

H. Tawbi, E. Keung, E. Burton, 2024, Nature cancer.

Impact of guideline adherence and expert center referral on the early management and outcomes of uterine sarcoma patients: A retrospective analysis from the French NETSARC network.

S. Piperno-Neumann, E. Laas, A. Hamy, 2023, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Pembrolizumab monotherapy for advanced chordoma - Authors' reply.

E. Bompas, F. Duffaud, Nicolas Penel, 2023, The Lancet. Oncology.

Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

M. Glabbeke, N. P. Erp, H. Guchelaar, 2022 .

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

M. von Mehren, H. Gelderblom, P. Schöffski, 2024, Nature medicine.

Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers

E. Pasquier, Clara Savary, Laura Broutier, 2023, Cell reports. Medicine.

Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.

J. Blay, S. Rodenhuis, M. van Glabbeke, 1999, Anti-cancer drugs.

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades

X. Buy, S. Mathoulin-Pélissier, M. Toulmonde, 2023, Cancers.

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

P. Rutkowski, H. Gelderblom, T. Gil, 2013, European journal of cancer.

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers

M. Tagliamento, L. Greillier, A. Toffart, 2024, NPJ precision oncology.

Artificial intelligence in oncology: ensuring safe and effective integration of language models in clinical practice

Jean-Yves Blay, L. Verlingue, Clara Boyer, 2024, The Lancet Regional Health - Europe.

Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study.

S. Bonvalot, J. Coindre, C. Linassier, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

J. Martín-Broto, A. Trama, S. Piperno-Neumann, 2024, The Lancet regional health. Europe.

Incidence and prognostic value of tumour cells detected by RT–PCR in peripheral blood stem cell collections from patients with Ewing tumour

M. Peter, J. Vermeulen, G. Pierron, 2006, British Journal of Cancer.